Anlotinib for Advanced and Refractory Natural Killer /T-cell Lymphoma

Phase 2 Completed 20 enrolled Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of anlotinib in patients with stage IV extranodal natural killer/T-cell lymphoma, nasal type.

Timeline

Start: 2018-07-25
Primary completion: 2021-04-30
Completion: 2021-04-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Catequentinib	Small molecule	12 mg	—

Anlotinib for Advanced and Refractory Natural Killer /T-cell Lymphoma

Summary

Timeline

Drugs

Indications